Califf: How FDA Tackles AI Drug Development Is ‘An Open Question’

FDA Commissioner Robert Califf told Inside Health Policy “it’s an open question right now” how the agency tackles drug makers’ use of artificial intelligence in drug development and suggested he hopes to use multiple public-private partnerships to tackle the issue. The comments following a Senate Appropriations hearing Wednesday (May 8) come as the agency’s biologics and drug center chiefs raised similar concerns this week. “There’s going to be so many different partnerships,” Califf told Inside Health Policy on...